Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
F-18 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| F-18 (BAY85-8050) | DRUG | Cancer patients, injection of BAY 85-8050, PET/CT |
Inclusion Criteria: * Healthy volunteers only * Males/females, \>/=50 and \</= 65 years of age * Cancer patients only * Males/females \>/= 35 years and \</= 75 years of age * Patient had an FDG PET/CT for detection, or staging, or restaging, or therapy response assessment that still showed tumor ma...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
F-18 is an investigational small molecule being studied for use in oncology, specifically for imaging in patients with neoplasms. It is a positron emission tomography/computed tomography (PET/CT) imaging agent. F-18 is currently in Phase 1 clinical development and is not approved by the FDA.
F-18 is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker BAYRY. The drug is currently in Phase 1 clinical development for oncology imaging applications.
F-18 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for use in positron emission tomography/computed tomography (PET/CT) imaging in patients with neoplasms.
F-18 has one completed Phase 1 clinical trial, NCT00961831, which evaluated radiation dosimetry, metabolism, safety, tolerability, and PET/CT imaging with BAY 85-8050 in healthy volunteers and patients with neoplasms. The trial enrolled 20 participants in Germany.
Yes, F-18 is also known as BAY 85-8050. The clinical trial NCT00961831 evaluated the safety, tolerability, and imaging properties of BAY 85-8050, which is the same investigational drug referred to as F-18.